Show simple item record

dc.contributor.authorMelia, J
dc.contributor.authorMoss, S
dc.contributor.authorJohns, L
dc.date.accessioned2018-09-11T09:59:57Z
dc.date.issued2004-07
dc.identifier1
dc.identifier.citationBJU INTERNATIONAL, 2004, 94 pp. 51 - 56
dc.identifier.issn1464-4096
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2621
dc.identifier.doi10.1111/j.1464-410X.2004.04832.x
dc.description.abstractObjective To assess the rate of prostate-specific antigen (PSA) testing for prostate cancer in general practice in asymptomatic and symptomatic patients. Subjects and Methods The cross-sectional study took place in England and Wales, was population-based and covered 469 159 men aged 45-84 years. Pathology data on PSA tests requested between 19 November 1999 and 31 May 2002 by general practitioners (GPs) were provided by 28 pathology laboratories. The practices recorded reasons for the tests between 1 December 2001 and 31 May 2002. In all, 391 practices in which all GP partners participated were included in the analyses. Results The overall annual rate of testing in men with no previous diagnosis of prostate cancer was estimated to be 6%, of which the annual rates of asymptomatic, symptomatic and re-testing were 2.0%, 2.8% and 1.2%, respectively, after adjusting for missing values. The rate decreased with increasing social deprivation, and with increasing proportions of black and Asian populations. The overall rate of PSA testing increased significantly from 1999 to 2002. Conclusions If the recommendations of the National Health Service Prostate Cancer Risk Management Programme were applied, 14% of asymptomatic tests and 23% of symptomatic tests would have led to a referral. As the rate of PSA testing is increasing and there are uncertainties about the benefit of screening, the workload and costs in general practice and hospitals should be monitored.
dc.format.extent51 - 56
dc.languageeng
dc.language.isoeng
dc.publisherBLACKWELL PUBLISHING LTD
dc.titleRates of prostate-specific antigen testing in general practice in England and Wales in asymptomatic and symptomatic patients: a cross-sectional study
dc.typeJournal Article
rioxxterms.versionofrecord10.1111/j.1464-410X.2004.04832.x
rioxxterms.licenseref.startdate2004-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBJU INTERNATIONAL
pubs.notesaffiliation: Melia, J (Reprint Author), Inst Canc Res, Canc Screening Evaluat Unit, Brookes Lawley Bldg,Cotswold Rd, Sutton SM2 5NG, Surrey, England. Inst Canc Res, Canc Screening Evaluat Unit, Sutton SM2 5NG, Surrey, England. keywords: prostate specific antigen; PSA; mass screening; prostatic neoplasms; primary health care; England; Wales keywords-plus: CANCER; UK research-areas: Urology & Nephrology web-of-science-categories: Urology & Nephrology author-email: [email protected] number-of-cited-references: 15 times-cited: 77 usage-count-last-180-days: 0 usage-count-since-2013: 0 journal-iso: BJU Int. doc-delivery-number: 832TM unique-id: ISI:000222290100013 da: 2018-09-10
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Breast Cancer Research/Aetiological Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Cancer Screening Evaluation Unit (DoH)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Aetiological Epidemiology
pubs.volume94
pubs.embargo.termsNot known
icr.researchteamCancer Screening Evaluation Unit (DoH)en_US
icr.researchteamAetiological Epidemiologyen_US
dc.contributor.icrauthorMoss, Susan Maryen
dc.contributor.icrauthorMelia, Janeen
dc.contributor.icrauthorJohns, Louiseen


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record